Authors:
Address: Bureau of Vector Borne Disease, Department of Disease Control, Ministry of Public Health, Muang district, Nonthaburi province, Thailand. k.congpuong@gmail.com
Journal:

Publication:

abstract

BACKGROUND & OBJECTIVES:

chloroquine (CQ), followed by 14 - day primaquine, is the recommended regimen for the treatment of Plasmodium vivax infection in Thailand. CQ resistant P. vivax (CRPv) has not yet challenged the efficacy of the drug. The present study was conducted to assess the current response of P. vivax to CQ alone in Thailand.

METHODS:

A 28-day in vivo therapeutic efficacy study was conducted from June 2009 to December 2010 in 4 sentinel sites. Recurrence of parasitaemia and the clinical condition of patients were assessed on each visit during follow -up. The drug levels in recurrent patients' blood were measured using HPLC. Data were analyzed using the WHO 2008 program for the analysis of in vivo tests.

RESULTS:

Of the total 212 patients included in the study, 201 completed the 28-days follow- up, while 11 were excluded. In five patients (2.5%), parasitaemia reappeared within the 28-days follow - up. On the day of recurrent parasitaemia, the level of chloroquine/desethylchloroquine (CQ - DCQ) was above the minimum effective concentration (>100 ng/ml) in one patient, but lower in four patients.

CONCLUSION:

Reappearance of the parasite within 28 days of follow - up in one of five patients was due to parasite resistance to CQ. The 2.5% prevalence of CQ treatment failure for P. vivax malaria in the study areas signals the need to launch monitoring activities for CQ resistant P. vivax in malaria endemic areas in order to detect further development of parasite resistance and to estimate the level of burden across the country.

Related Articles
Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia.
Malar J. 2009
Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia.
Ketema T, Bacha K, Birhanu T, Petros B. Malar J. 2009 Jul 30; 8:177. Epub 2009 Jul 30.
Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia.
Malar J. 2008
Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia.
Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S, Kokwaro G, Aseffa A, Engers H. Malar J. 2008 Oct 29; 7:220. Epub 2008 Oct 29.
Clinical response and susceptibility in vitro of Plasmodium vivax to the standard regimen of chloroquine in Thailand.
Trans R Soc Trop Med Hyg. 1995
Clinical response and susceptibility in vitro of Plasmodium vivax to the standard regimen of chloroquine in Thailand.
Tan-ariya P, Na-Bangchang K, Tin T, Limpaibul L, Brockelman CR, Karbwang J. Trans R Soc Trop Med Hyg. 1995 Jul-Aug; 89(4):426-9.
Review Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries.
Trans R Soc Trop Med Hyg. 2010
Review Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries.
Naing C, Aung K, Win DK, Wah MJ. Trans R Soc Trop Med Hyg. 2010 Nov; 104(11):695-705. Epub 2010 Sep 20.
Review Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels.
Am J Trop Med Hyg. 1997
Review Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels.
Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, Wignall FS, Hoffman SL. Am J Trop Med Hyg. 1997 Jun; 56(6):621-6.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster